Saturday 17 October 2026
Export AKTS’s income statement to Excel — free account
Aktis Oncology, Inc.
AKTS Healthcare Biotechnology
Aktis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.5 million, up 336.9% from fiscal 2024. Insiders bought in the last twelve months.
15.06
0.95
−5.93%
Follow AKTS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 76 | 79 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.02 | 0.08 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 1 | 6 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | 100.00 | 100.00 | |||||
| EBT | — | — | — | — | — | — | — | (29) | (44) | (64) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | (2,957.63) | (980.93) | |||||
| Net income | — | — | — | — | — | — | — | (29) | (44) | (64) | |||||
| Depreciation | — | — | — | — | — | — | — | (2) | (3) | (2) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 2.11 | 7.99 | ||||
| Earnings | — | — | — | — | — | — | — | (46.55) | (62.46) | (78.34) | |||||
| Cash flow | — | — | — | — | — | — | — | (48.77) | 20.96 | (78.83) | |||||
| Capex | — | — | — | — | — | — | — | (6.03) | (4.06) | (11.78) | |||||
| Free cash flow | — | — | — | — | — | — | — | (54.80) | 16.90 | (90.61) | |||||
| Book value | — | — | — | — | — | — | — | 168.63 | 348.77 | 230.19 | |||||
| Shares, m | — | — | — | — | — | — | — | 1 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | 2.11 | 2.11 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (30) | 15 | (64) | ||||
| Capex | — | — | — | — | — | — | — | (4) | (3) | (10) | |||||
| Free cash flow | — | — | — | — | — | — | — | (34) | 12 | (74) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 94 | 282 | 199 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | (98) | (297) | (227) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | 104 | 246 | 187 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (19.61) | (21.56) | ||||
| ROIC | — | — | — | — | — | — | — | (369.71) | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 65.59 | 54.48 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Aktis Oncology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics, Inc. | $901.0M | — (loss-making) | 4.8× | — | n/m | +33.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| AKTS Aktis Oncology, Inc. | $890.5M | — (loss-making) | — (loss-making) | — | n/m | −12.77% (below 0%: shrinking) | 100.00% | (853.99%) | |
| ANRO Alto Neuroscience, Inc. | $887.7M | — (loss-making) | — | — | n/m | −43.41% (below 0%: shrinking) | — | 0.00% | Compare |
| RIGL Rigel Pharmaceuticals, Inc. | $882.6M | 2.6× | 7.9× | −22.60% (below 0%: shrinking) | −72.07% (below 0%: shrinking) | −229.99% (below 0%: shrinking) | 89.17% | 29.95% | Compare |
| JBIO Jade Biosciences, Inc. | $875.1M | — (loss-making) | — | — | n/m | −115.11% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MLTX MoonLake Immunotherapeutics | $873.2M | — (loss-making) | — | — | n/m | −1.89% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GLUE Monte Rosa Therapeutics, Inc. | $863.4M | — (loss-making) | — (loss-making) | −61.33% (below 0%: shrinking) | n/m | −34.11% (below 0%: shrinking) | 100.00% | (547.84%) | Compare |
| KURA Kura Oncology, Inc. | $862.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| ALMS Alumis Inc. | $842.4M | — (loss-making) | — (loss-making) | −37.66% (below 0%: shrinking) | n/m | +23.59% (above 0%: growing) | 100.00% | (8,956.38%) | Compare |
| Median of peers | $874.1M | — | — | −30.13% | — | −38.76% | 98.84% | 0.00% |
Aktis Oncology, Inc. (AKTS) key facts
- Concern: Aktis Oncology, Inc. reported a net loss of $63.7 million, or a loss of $78.34 per share, for fiscal 2025.
- Strength: Aktis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.5 million, up 336.9% from fiscal 2024.
- Aktis Oncology, Inc. (AKTS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, AKTS traded at $15.06, a market capitalization of $890.5 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 86.2× sales.
- Return on equity was 54.5% and debt-to-equity 0.00.
Aktis Oncology, Inc. (AKTS) Latest News
No news at this impact. Lower the threshold for more.